EGFR and non-small cell lung carcinoma: A new study was carried out using cell membrane protein-based biomimetic NPs encapsulated DOX and icotinib to EGFR-mutant NSCLC, which achieved high drug accumulation in tumors and enhanced cytotoxicity of the chemotherapeutic drugs.